These extend from systemic ICIs monotherapy to combinations with chemotherapy or targeted therapies in cases with relevant tumor mutations (e.g., BRAF/MEK in melanoma and EGFR in non-small cell lung cancer, NSCLC). The gene discussed is BRAF; the disease is non-small cell lung carcinoma.